-
Top 10 Diabetes Medications to Watch in 2024
Diabetes
Discover the top 10 diabetes medications of 2024, including Ozempic, Jardiance, and Mounjaro. Learn about their sales, innovations, and why they're leading in the treatment of diabetes and related conditions.
-
Merck: Termination of Two Oncology Projects
Merck
Merck announces the termination of two oncology projects: Vibostolimab (anti-TIGIT) and Favezelimab (anti-LAG-3), citing safety concerns and failure to meet clinical endpoints in key trials.
-
MK-3475A-D77 Study Success
Merck
Merck's Phase III MK-3475A-D77 study shows positive results for subcutaneous pembrolizumab (MK-3475A) compared to intravenous Keytruda, improving patient experience and accessibility for metastatic NSCLC treatment.
-
$1.3 Billion! Merck Acquires a Biotech Company
Merck
Merck has acquired Modifi Biosciences for up to $1.3 billion, securing rights to its experimental cancer therapy, KL-50, aimed at treating hard-to-treat brain tumors like gliomas. This deal includes a $30 million upfront payment, with potential milestone payments.
-
-
-
张家界市|
延吉市|
白玉县|
久治县|
柞水县|
大英县|
南平市|
河北区|
姚安县|
仪陇县|
连云港市|
台北市|
湛江市|
内丘县|
普定县|
溧水县|
镇远县|
宁海县|
大英县|
柳林县|
中方县|
新平|
宁乡县|
花莲市|
宜都市|
福海县|
上犹县|
江孜县|
瓦房店市|
仁化县|
府谷县|
霍林郭勒市|
芦溪县|
武胜县|
巩留县|
延寿县|
胶南市|
惠东县|
太白县|
花莲县|
隆尧县|